Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2008

View Archived Issues

Sirolimus investigated in diabetic macular edema, age-related macular degeneration

EGb-761 demonstrates efficacy in dementia with neuropsychiatric features

DSMB reports positive review of BioMS' phase II MINDSET-01 trial of MBP-8298 in MS

Huya completes three phase I clinical trial protocols for HBI-3000 in China

Affinium initiates dosing in phase I study of antistaphylococcal antibiotic AFN-1252

Axcan reports results for Q1 2008

Phase I/IIa trial set to commence for long-acting recombinant FIX:Fc for hemophilia B

Vivus completes patient enrollment in EQUATE (OB-301) trial

FDA grants priority review for GlaxoSmithKline's Promacta/Revolade for ITP

Fujirebio is granted CE marking for HE4 test for ovarian cancer

Genmab and Pepscan enter research collaboration

Recent LG patent imparts novel treatment option for inflammatory disorders

Vaccine based on combined virus-like particles protects from hemorrhagic fever infection

PolyMedix antimicrobial polymers show enhanced activity in combination with sesquiterpenoids

Pluristem submits pre-IND application in Germany for PLX-PAD for peripheral artery disease

PsychoGenics and Dainippon Sumitomo enter drug discovery agreement for CNS disorders

Alnylam reports results from phase II GEMINI clinical trial of ALN-RSV01

Incyte provides Q4 and full-year 2007 results

Ception initiates phase II/III reslizumab trial in eosinophilic esophagitis

Pfizer announces tender offer for all outstanding Encysive shares

Phase I/II studies of IMC-A12 commence patient enrollment in pediatric cancer patients

Fondation Charcot Stichting to initiate phase I/II trial of Cell Therapeutics' pixantrone

Kyowa Hakko and Amgen enter agreement for humanized monoclonal antibody KW-0761

BTG initiates phase I clinical study of BGC20-0134 for multiple sclerosis

Novel treatment options for metabolic disorders reported in recent patents

Recent patents describe new antidiabetic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...